7月21日，派格生物医药-B盘中上涨8.04%，报7.39港元，成交额1.47亿港元。
消息面上，7月17日，派格生物医药-B与上海腾瑞制药及阿里健康在杭州正式签署战略合作协议，三方将整合医药研发、生产及数字化健康服务资源，共同推进核心产品派达康（维培那肽注射液）的商业化进程。派达康已获批用于成人2型糖尿病治疗，属独家品种，并已通过国家医保目录调整初步形式审查。此外，公司此前已收到腾瑞制药支付的首笔权益金6100万港元，并与Rani Therapeutics签署备忘录推进代谢资产口服化开发。市场关注重点已由产品获批转向医院覆盖及线上线下协同带来的放量速度。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.